Asep Medical Holdings Inc. announced that the Company's AI-based sepsis diagnostic technology, called Sepset, has received successful patent approval in the United States. The Company received confirmation from its attorneys of its US Patent Application No. 16/279788, which has been subsequently validated in the US, representing 332 million people.

This patent is in addition to the successful European and Australian patents awarded to the Company in November of 2022, which represent approximately 400 million people. The US patent, granted on August 18, 2023, is exclusively licensed to Asep Inc.'s subsidiary Sepset Biosciences Inc. and validates the Company's unique AI-based approach to sepsis diagnosis, a disease that globally causes more than 11 million deaths annually. Sepset is a blood-based gene expression assay developed under the direction of leading UBC microbiologist and Asep Inc.'s Founder, Chair & CEO, Dr. Robert E. W. Hancock.

The test enables earlier and faster risk assessment of sepsis and enables targeted treatment. Sepsis is also the cause of death in most patients with severe COVID-19. The Sepset test senses the dysfunctional immune response underlying sepsis when patients first enter the emergency room.

The test is a blood-based gene expression assay that is straightforward to implement using equipment available in most hospital labs, and results are obtained in about 60-90 minutes. Current diagnostic tools deliver results after approximately 8-36 hours, often delaying the initiation of treatment. Sepset is designed to enable physicians to quickly predict how severe the disease will become and thus trigger urgent patient treatment.